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Abstract
Aims/hypothesis Glucagon like peptide-1 (GLP-1) enhances
glucose-dependent insulin secretion by binding to GLP-1 re-
ceptors (GLP1Rs) on pancreatic beta cells. GLP-1 mimetics
are used in the clinic for the treatment of type 2 diabetes, but
despite their therapeutic success, several clinical effects of
GLP-1 remain unexplained at a mechanistic level, particularly
in extrapancreatic tissues. The aim of this study was to gener-
ate and characterise a monoclonal antagonistic antibody for
the GLP1R for use in vivo.
Methods A naive phage display selection strategy was used to
isolate single-chain variable fragments (ScFvs) that bound to
GLP1R. The ScFv with the highest affinity, Glp1R0017, was
converted into a human IgG1 and characterised further. In vitro
antagonistic activity was assessed in a number of assays: a
cAMP-based homogenous time-resolved fluorescence assay in
GLP1R-overexpressing cell lines, a live cell cAMP imaging as-
say and an insulin secretion assay in INS-1 832/3 cells.
Glp1R0017 was further tested in immunostaining of mouse pan-
creas, and the ability of Glp1R0017 to block GLP1R in vivo was
assessed by both IPGTT and OGTT in C57/Bl6 mice.
Results Antibodies to GLP1R were selected from naive anti-
body phage display libraries. The monoclonal antibody
Glp1R0017 antagonised mouse, human, rat, cynomolgus mon-
key and dog GLP1R. This antagonistic activity was specific to
GLP1R; no antagonistic activity was found in cells overexpress-
ing the glucose-dependent insulinotropic peptide receptor
(GIPR), glucagon like peptide-2 receptor or glucagon receptor.
GLP-1-stimulated cAMP and insulin secretion was attenuated in
INS-1 832/3 cells by Glp1R0017 incubation. Immunostaining of
mouse pancreas tissue with Glp1R0017 showed specific staining
in the islets of Langerhans, which was absent inGlp1r knockout
tissue. In vivo, Glp1R0017 reversed the glucose-lowering effect
of liraglutide during IPGTTs, and reduced glucose tolerance by
blocking endogenous GLP-1 action in OGTTs.
Conclusions/interpretation Glp1R0017 is a monoclonal an-
tagonistic antibody to the GLP1R that binds to GLP1R on
pancreatic beta cells and blocks the actions of GLP-1
in vivo. This antibody holds the potential to be used in inves-
tigating the physiological importance of GLP1R signalling in
extrapancreatic tissues where cellular targets and signalling
pathways activated by GLP-1 are poorly understood.
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Cmax Maximal concentration
ECD Extracellular domain
FRET Fluorescence resonance energy transfer
GIP Glucose-dependent insulinotropic peptide
GIPR Glucose-dependent insulinotropic peptide receptor
GLP-1 Glucagon like peptide-1
GLP1R Glucagon like peptide-1 receptor
GLP2R Glucagon like peptide-2 receptor
GPCR G-protein-coupled receptor
HTRF Homogenous time-resolved fluorescence
IBMX 3-isobutyl-1-methylxanthine
ScFv Single-chain variable fragment
tdRFP Tandem red fluorescent protein
YFP Yellow fluorescent protein
Introduction
The incretin hormone glucagon like peptide-1 (GLP-1) is se-
creted from enteroendocrine L cells following ingestion of
food, and enhances glucose-dependent insulin secretion by
activating GLP-1 receptors (GLP1R) on pancreatic beta cells
[1]. GLP-1 mimetics are available in the clinic for the treat-
ment of type 2 diabetes [2], but several effects of GLP-1 re-
main unexplained at a mechanistic level, particularly in
extrapancreatic tissues.
When considering GLP1R expression, the field of re-
search has been limited by a lack of specificity of com-
mercially available GLP1R antibodies [3]. GLP1R is a G-
protein-coupled receptor (GPCR); thus, generating anti-
bodies is inherently difficult due to the seven transmem-
brane domains of the receptor. An alternative method for
studying receptor expression has been transgenic expres-
sion of fluorescent reporters downstream of the Glp1r
promoter [4]. Aside from this, the monoclonal antibody
mAb3F52 with specificity for human and monkey GLP1R
has been generated and used in immunostaining [5].
Combined, these methods have been used to report
GLP1R expression across several tissues [4–6].
The seemingly widespread expression of GLP1R sug-
gests that GLP-1 has a number of functions apart from
enhancing glucose-induced insulin secretion. Within the
pancreas, GLP-1 inhibits glucagon secretion from alpha
cells, and stimulates somatostatin secretion from delta
cells. Other proposed functions include stimulation of na-
triuresis in the kidneys, decrease of food intake via sig-
nalling in the central nervous system, modulation of heart
rate, and cardioprotection in myocardial ischaemia [7].
Physiological effects of GLP-1 mimetics in the clinic in-
clude decreased cardiovascular risk and increased risk of
retinopathy, although this varies between studies and may
depend on the agonist used [8–10]. Uncertainty surrounds
whether these additional effects are mediated directly via
GLP1R on affected tissues, indirectly via GLP1R activa-
tion in neurons or through GLP1R-independent pathways
[11].
GLP1R antagonists could be used to address some of these
functional questions. The objective of this study was to gen-
erate and characterise a monoclonal antagonistic antibody for
GLP1R that could be used to block GLP1R signalling in vivo.
In comparison to the peptide antagonist exendin 9–39, an
antibody would provide the advantage of having an extended
half-life for use in subchronic functional studies. As off-target
effects have also been observed for exendin 9–39 [12], anoth-
er major advantage of a GLP1R antagonistic antibody is spec-
ificity for GLP1R. Here we developed an antagonistic anti-
body against GLP1R, and characterised it in a number of
in vitro assays and in vivo studies using lean C57/Bl6 mice,
which are well established for studying glucose homeostasis
in the context of diabetes.
Methods
Compounds and solutions Unless otherwise stated,
chemicals were obtained from Sigma-Aldrich (Poole, UK).
Peptides were purchased from Bachem (Bubendorf,
Switzerland). The GLP1R extracellular domain (ECD) was
produced in Escherichia coli, purified as previously described
[13] and biotinylated using EZ-link Sulfo-NHS-LC-Biotin
(Thermo Fisher Scientific, Loughborough, UK).
Saline solution for imaging experiments contained
(mmol/l): 138 NaCl, 4.5 KCl, 4.2 NaHCO3, 1.2 NaH2PO4,
2.6 CaCl2, 1.2 MgCl2 and 10 HEPES (pH 7.4, NaOH).
KRB contained (mmol/l): 120 NaCl, 3.5 KCl, 1.2 KH2PO4,
1.2 MgSO4, 2.5 CaCl2, 25 NaHCO3 (pH 7.2, NaOH). Assay
buffer for calcium measurements and ligand-binding assays
was Hanks’ balanced salt solution supplemented with
25 mmol/l HEPES and 0.1% (wt/vol.) BSA (pH 7.4); for the
cAMP homogenous time-resolved fluorescence (HTRF)
assay, the buffer was also supplemented with 0.5 mmol/l
3-isobutyl-1-methylxanthine (IBMX).
Cell cultureAll cell lines used in this study were mycoplasma
negative. INS-1 832/3 cells were maintained in RPMI 1640
Media with GlutaMAX supplement (Thermo Fisher
Scientific), 10% FBS, 10 mmol/l HEPES, 50 μmol/l 2-
mercaptoethanol, 1 mmol/l sodium pyruvate and penicillin/
streptomycin at 37°C in 5% CO2 [14]. Stably transfected cell
lines overexpressing GPCRs were generated at AstraZeneca
(Gothenburg, Sweden) or MedImmune (Cambridge, UK)
using public-domain- or in-house-determined sequences for
each receptor, with parental lines purchased from ATCC,
ECACC or Invitrogen [15–17]. Overexpressing cell lines for
experimental use were thawed from liquid nitrogen stocks into
assay buffer on the day of the experiment for cAMP HTRF
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assays, and responses to agonist were assessed to confirm
expected cell activity. A mirrorball system (TTP Labtech,
Melbourn, UK) was used for the receptor ligand binding as-
say, described in detail in ESM Methods [18].
Phage display selections
The bone marrow vault library (BMVtrp), combined spleen
library (CStrp) and DP47 library (DP47trp) were used for phage
selections of single-chain variable fragments (ScFvs) that
bound to the GLP1R. The first two rounds of selections, on
100 and 50 nmol/l soluble biotinylated human GLP1R ECD,
respectively, were performed as previously described [16, 19].
For the third round of selection, cell surface selections were
carried out on Chinese hamster ovary (CHO) cells overex-
pressing mouse GLP1R. Variable genes from antibodies of
interest were cloned into pEU expression vectors for expres-
sion and purification of IgGs, as previously described [20].
cAMP HTRF accumulation assay Cell-based cAMP HTRF
accumulation assays were used to screen Glp1R0017 for ac-
tivity in overexpressing cell lines. Serial dilutions of the anti-
body and control peptides were prepared in assay buffer and
plated using an ECHO525 acoustic liquid handler (Labcyte,
Sunnyvale, CA, USA) to give an 11 point dose–response
curve in duplicate. Cells were resuspended in assay buffer
and then combined with serially diluted antibodies/peptides
for 15 min of incubation at room temperature. An agonist
challenge based on GLP-1 dose–response curves (see elec-
tronic supplementary material [ESM] Fig. 1) was added to
samples using the ECHO550 acoustic liquid handler
(Labcyte), and samples were centrifuged at 150 g for 1 min
for mixing. Following 30 min of incubation at room temper-
ature, cellular cAMP levels were measured using a cAMP
dynamic 2 HTRF kit (Cisbio, Codolet, France) according to
the manufacturer’s recommendations. After 1 h, plates were
read on an EnVision plate reader (PerkinElmer, Waltham,
MA, USA). This assay was also used for Schild analysis of
Glp1R0017 in the CHO mGLP1R cell line. EC50 values were
calculated using non-linear regression in GraphPad Prism
(San Diego, CA, USA); dose ratios were determined and plot-
ted to calculate dissociation constants.
Calcium measurements CHO cells overexpressing human
GLP1R were cultured in black poly-D-lysine-coated 384-
well plates (15,000 cells/well; Greiner Bio-One, Stonehouse,
UK) at 37°C overnight. Cells were washed with assay buffer,
loaded with Fluo-4 NW containing 2.5 mmol/l probenecid
(Thermo Fisher Scientific) for 30 min (37°C) and 15 min
(room temperature), and then incubated with antibody for
15 min at room temperature before adding GLP-1.
Fluorescence was recorded using FLIPR Tetra (Molecular
Devices, Wokingham, UK) every 0.5 s for 1 min after agonist
addition, followed by every 3 s for a further 4 min. Individual
responses were normalised to vehicle control, and average
responses were calculated by subtracting the basal fluores-
cence from the peak intensity. Statistical significance was
assessed by one-way ANOVAwith post hoc Bonferroni test.
cAMP FRET measurements Single-cell measurements of
cAMP were made using the fluorescence resonance energy
transfer (FRET)-based sensor Epac2-camps [21], based on
the method described for GLUTag cells [22]. INS-1 832/3
cells were seeded into 35 mm plastic dishes and, when 70–
80% confluent, were transfected with 3 μg Epac2-camps
DNA probe using 3μl lipofectamine 2000 for 24 h. Cells were
trypsinised and re-seeded onto Matrigel-coated 35 mm glass-
bottomed dishes for experiments 24–48 h later. For each ex-
periment, cells were washed with saline and then continuously
perfused with saline ± test reagents. For the antibody experi-
ment, cells were preincubated with 100 μmol/l Glp1R0017
diluted in saline for 15 min prior to the start of imaging.
Cells were visualised with a ×40 oil immersion objective
on an inverted microscope (IX71; Olympus Southend on Sea,
UK). A xenon arc lamp coupled to a monochromator (Cairn
Research, Faversham, UK) controlled by MetaFluor software
(Molecular Devices) was used to excite the cells at 435 nm
(200–225 ms excitations) every 5 s. Cyan fluorescent protein
(CFP) emission (470 nm) and yellow fluorescent protein
(YFP) emission (535 nm) were monitored using an
Optosplit II beam splitter (Cairn Research) and an Orca-ER
digital camera (Hamamatsu, Welwyn Garden City, UK), and
expressed as the CFP/YFP fluorescence ratio. A sliding aver-
age across 30 s was used, and responses were calculated by
subtracting the maximum ratio at baseline from the maximum
ratio during application of the test reagent. Changes in the
CFP/YFP emission ratio were calculated as mean ± SEM,
and statistical significance was assessed by one-way
ANOVAwith post hoc Bonferroni test.
Insulin secretion assays Twenty-four hours before insulin
secretion, INS-1 832/3 cells were seeded in 24-well plates at
5 × 105 cells/well. Cells were washed in PBS and then incu-
bated with or without Glp1R0017 in KRB containing 0.2%
BSA for 1 h at 37°C in 5%CO2. Cells were then incubated for
2 h with test reagents in KRB. Supernatant fractions were
collected and centrifuged to remove any cell debris. Insulin
was measured in the supernatant fractions using a rat insulin
assay (Meso Scale Discovery, Gaithersburg, MD, USA).
Statistical significance was assessed by one-way ANOVA
with post hoc Bonferroni test.
Animals All animal care and experimental procedures were
performed in accordance with the Animal (Scientific
Procedures) Act 1986, local establishment usage guidelines
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and Animal Research: Reporting of In Vivo Experiments
(ARRIVE) guidelines. The Project Licences authorising the
work were approved by a local ethical review body (Animal
Welfare and Ethical Review Body). C57/Bl6 mice were
sourced from Charles River UK and group-housed in individ-
ually ventilated cages within a barrier unit with 12 h light/dark
cycle and ad libitum access to chow diet and water. For the
experiments, mice were randomised according to body
weight.
Immunostaining Pancreas tissue was fixed in 4% (wt/vol.)
paraformaldehyde, dehydrated in 15% (wt/vol.) and 30% (wt/
vol.) sucrose and frozen in optimal cutting temperature em-
bedding media (VWR Chemicals, Radnor, PA, USA).
Sections were cut (7–10 μm) using a cryostat and mounted
directly on to Superfrost Plus glass slides (Thermo Fisher
Scientific). Slides were incubated for 1 h in blocking solution
containing 5% (vol./vol.) serum, 0.05% (vol./vol.) Tween-20
and 1% (wt/vol.) BSA, and then overnight in blocking solu-
tion with the primary antisera of interest against insulin, glu-
cagon, GLP1R and tandem-RFP (ESM Table 1). Slides were
washed with blocking solution and incubated with appropriate
secondary antisera diluted to 1:300 for 1 h. Negative control
slides were stained with secondary antisera alone. Cover slips
were mounted using Hydromount (National Diagnostics,
Atlanta, GA, USA) and DABCO before confocal microscopy
(TCS SP8; Leica, Wetzlar, Germany).
Brain tissue was collected from mice perfused in situ with
4% (wt/vol.) paraformaldehyde and stored in 4% paraformal-
dehyde 30% (wt/vol.) sucrose prior to slicing at 25 μm.
Sections were stained in suspension after sodium citrate anti-
gen retrieval using protocols otherwise similar to those for
pancreatic tissue, apart from the blocking solution, which
did not contain any BSA.
Single-dose pharmacokinetics studyTwo groups of six male
C57/Bl6 mice (13 weeks old, mean weight 29.1 ± 0.2 g) were
administered Glp1R0017 at 19.2 mg/kg either intraperitone-
ally or subcutaneously. A sparse sampling approach was used,
collecting blood samples from animals across the groups at
0.5, 1, 2, 4 and 7 h after antibody dosing, and then every 24 h
over a period of 5 days. At the 120 h endpoint, the animals
were terminally anaesthetised using isoflurane inhalation,
blood samples were collected via cardiac puncture, and death
confirmed via cervical dislocation. Blood samples were col-
lected into EDTA capillary tubes and centrifuged to obtain
plasma. Quantitative analysis of plasma antibody concentra-
tion was performed in a Gyrolab assay according to the man-
ufacturer’s guidelines (Gyros, Uppsala, Sweden), using a bi-
otinylated idiotype antibody against IgG1 for capture
(MedImmune, Cambridge, UK), and an Alexa-labelled sheep
anti-human IgG for detection (The Binding Site, Birmingham,
UK).
IPGTTs and OGTTs GTTs were performed in 10-week-old
male C57/Bl6 mice (mean weight: IPGTT 27.7 ± 0.2 g, OGTT
25.5 ± 0.3 g) after a 6 h fast, using n = 8 per group determined
by power analysis where the effect size was 15%, and 80%
power and significance <0.05. Depending on the group
(detailed in Results), animals were dosed subcutaneously with
antibody or saline 24 h prior to the GTT.
For the IPGTT, mice were dosed with 0.1 mg/kg liraglutide
(Victoza; Novo Nordisk, Gatwick, UK) or vehicle subcutane-
ously 2 h before intraperitoneal glucose administration
(2 g/kg). Blood glucose levels were determined from tail-
prick blood samples using a hand-held glucometer
(AlphaTrak; Zoetis, London, UK) at −120, 0, 15, 30, 45, 60,
90 and 120 min relative to the glucose challenge. For the
OGTT, mice were orally gavaged with glucose (2 g/kg), and
blood glucose levels were determined at 0, 15, 30, 45, 60, 90
and 120 min relative to the glucose challenge. At the end of
the experiment, animals were euthanised using cervical dislo-
cation. The AUC between 0 and 120 min was calculated, and
statistical significance was assessed by one-way ANOVAwith
post hoc Bonferroni test.
Results
Selection of GLP1R antagonistic antibodies Antibodies
targeting the GLP1R were generated using naive phage dis-
play libraries in a series of selections on biotinylated human
GLP1R ECDs, and cell surface selections on mouse GLP1R-
overexpressing CHO cells. Following the third round of se-
lection, clone diversity and enrichment was assessed by se-
quencing. Eighteen ScFv clones enriched in the cell surface
selections were selected for functional analysis. The ability of
ScFvs to antagonise GLP-1 stimulated cAMP production was
assessed in a cell-based HTRF assay using mGLP1R-
overexpressing CHO cells. Seven unique clones were identi-
fied as antagonistic, of which Glp1R0017 had the lowest IC50
value (238 nmol/l). On conversion into the IgG1 format,
Glp1R0017 retained antagonistic activity and increased in po-
tency (IC50 = 5.2 nmol/l; Fig. 1a).
Glp1R0017 is a specific, competitive antagonist at the
GLP1R across multiple species Species cross-reactivity of
Glp1R0017 was determined using a panel of CHO cells over-
expressing mouse, rat, human, dog or cynomolgus monkey
GLP1R in a cAMP-based HTRF assay. GLP-1 agonism was
first assessed to determine an appropriate agonist challenge
for each cell line (ESM Fig. 1). Glp1R0017 displayed antag-
onistic activity in each species assessed, and IC50 values were
calculated (Fig. 1a, ESM Table 2). IC50 values ranged from
5.2 to 43 nmol/l, although these might have been affected by
levels of GLP1R overexpression (ESM Methods and ESM
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Fig. 2). No Glp1R0017 agonist activity was observed at the
mouse or human GLP1R (data not shown).
Specificity of Glp1R0017 for GLP1R was demonstrated
with a cAMP assay using a panel of cell lines overexpressing
other class B GPCRs. The antagonistic activity of Glp1R0017
was specific to GLP1R; no antagonistic activity was found in
cells overexpressing the glucose-dependent insulinotropic
peptide receptor (GIPR), glucagon like peptide-2 receptor
(GLP2R) or glucagon receptor (Fig. 1b–d). In addition to
cAMP responses, Glp1R0017 inhibited GLP-1-induced intra-
cellular calcium responses in CHO cells overexpressing hu-
man GLP1R (Fig. 1e, f).
The in vitro pharmacology of the antagonistic activity of
Glp1R0017 on mouse GLP1R was investigated using Schild
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Fig. 1 Glp1R0017 antagonises GLP-1-induced cAMP production in
GLP1R-overexpressing cell lines, and has no effect on GIPR, GLP2R
or glucagon receptor (GCGR) activity. Glp1R0017 was characterised
for antagonism of GLP1R, GIPR, GLP2R and GCGR in a cell-based
cAMP HTRF assay, and data were plotted using non-linear regression.
(a) Antagonistic profiles of Glp1R0017 in CHO cells overexpressing
mouse (circle), human (upright triangle), rat (square), cynomolgus mon-
key (inverted triangle) and dog (diamond) GLP1R. (b) Antagonistic pro-
files of Glp1R0017 (open symbols) and the antagonistic GIPR antibody
Gipg013 (filled symbols) in CHO cells overexpressing human GIPR
(triangles), and HEK293 cells overexpressing mouse GIPR (circles). (c)
Antagonistic profile of Glp1R0017 in HEK293 cells overexpressing hu-
man GLP2R. (d) Antagonistic profiles of Glp1R0017 (white symbols)
and the glucagon receptor antagonist des-His1-[Glu9]-glucagon (1–29)
amide (black symbols) in CHO cells overexpressing human (triangles),
mouse (circles) and rat (squares) GCGR. (a–d) Values have been normal-
ised to themaximum activity of each receptor, defined by the total cellular
cAMP production in the absence of peptide/IgG. Data are mean ± SE
from duplicate wells, and the data shown are representative of at least
three separate experiments. (e) Representative intracellular calcium re-
sponses of CHO human GLP1R cells to 5 μmol/l GLP-1 (blue), +
1 μmol/l Glp1R0017 (red trace), + 1 μmol/l R347 isotype control (green)
or vehicle control (purple). Traces were normalised (norm.) to the vehicle
control. (f) Mean intracellular calcium responses were measured in rela-
tive fluorescent units (RFU). Responses were calculated by subtracting
basal fluorescence at 19 s from peak intensity. Data are mean ± SD, n = 16
wells (eight wells from each of two independent experiments). Statistical
significance was assessed by one-way ANOVAwith post hoc Bonferroni
test. ***p < 0.001
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regression analysis, in which the effect of increasing concen-
trations of Glp1R0017 on GLP-1 dose–response curves was
assessed. The maximum cAMP response to GLP-1 was not
reduced by increasing Glp1R0017 concentrations, showing
that the antagonistic effect of Glp1R0017 is not insurmount-
able (Fig. 2a). The same was observed with exendin 9–39
(Fig. 2b). The slope gradient of the Schild regression analysis
for Glp1R0017 was 0.56, and the calculated dissociation con-
stant was 466 pmol/l. Exendin 9–39 had a slope gradient of
0.89 and a calculated dissociation constant of 315 pmol/l (Fig.
2c).
Glp1R0017 inhibits GLP1R function in INS-1 832/3 cells
Glp1R0017 was further characterised in INS-1 832/3 cells to
show antagonistic activity on endogenous levels of GLP1R.
Two aspects of GLP1R antagonism were assessed: antago-
nism of the cAMP response in live cell imaging, and antago-
nism of insulin secretion.
To enable live cell measurement of cAMP, INS-1 832/3
cells were transfected with a FRET-based cAMP sensor, and
the CFP/YFP ratio was recorded over time. A concentration of
100 nmol/l GLP-1 stimulated increases in cAMP (Fig. 3a),
and this elevation in cAMP was reduced in cells preincubated
with 1 μmol/l Glp1R0017 (Fig. 3b). Overall, preincubation of
INS-1 832/3 cells with Glp1R0017 reduced the GLP-1-
stimulated cAMP response by 64% (p < 0.001). In compari-
son, Glp1R0017 preincubation had no effect on forskolin/
IBMX cAMP responses (Fig. 3c).
GLP1R activation and the subsequent increase in cAMP
stimulated insulin secretion from pancreatic beta cells.
Concentrations of 10 nmol/l GLP-1, 100 nmol/l GLP-1 and
10 nmol/l glucose-dependent insulinotropic peptide (GIP)
stimulated insulin secretion, by 1.4-fold, 2-fold and 2.9-fold,
respectively, in INS-1 832/3 cells. On incubation with
Glp1R0017, 10 nmol/l GLP-1-stimulated insulin secretion
was reduced from 1.4-fold to 0.8-fold (p < 0.01), whereas
there was no significant effect on 10 nmol/l GIP-stimulated
insulin secretion (Fig. 3d). This confirmed that Glp1R0017
specifically inhibited the function of GLP1R activation, with
no off-target effects on the GIPR.
Glp1R0017 binds and inhibits the function of GLP1R
in vivo Following in vitro characterisation of Glp1R0017,
pancreas tissue was collected from Glp1r-Cre/ROSA26-
tdRFP mice [4] and Glp1r−/− mice [23]. The fixed and frozen
tissue was used in immunostaining with Glp1R0017. In
Glp1r-Cre/ROSA26-tdRFP tissue, Glp1R0017 bound to cells
expressing the tandem red fluorescent protein (tdRFP) report-
er in the islets of Langerhans and arcuate nucleus region (Fig.
4a, c). This immunostaining was depleted in control Glp1r−/−
pancreas tissue, again showing that Glp1R0017 is specific for
the GLP1R (Fig. 4b). This gave confidence that administra-
tion of Glp1R0017 to mice for functional studies would lead
to GLP1R binding.
Prior to functional studies in vivo, the pharmacokinetic
properties of Glp1R0017 were assessed in C57/Bl6 mice over
5 days. A maximal concentration (Cmax) of 2.1 μmol/l was
reached 4 h after 19.2 mg/kg intraperitoneal dosing, compared
with a Cmax of 1.7 μmol/l reached 24 h after 19.2 mg/kg
subcutaneous dosing. At 120 h, the plasma concentration of
Glp1R0017 was 0.9 μmol/l for the intraperitoneally dosed
group, and 1 μmol/l for the subcutaneously dosed group
(Fig. 5). Subcutaneous dosing was used for functional studies,
24 h prior to experiments.
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Fig. 2 Glp1R0017 antagonism of themouseGLP-1R is reversed through
competition with GLP-1. (a) Dose–response curves of GLP-1 in the pres-
ence of Glp1R0017 at varying concentrations in CHO cells overexpress-
ing mouse GLP1R. Concentrations of Glp1R0017 were: 4.1 nmol/l
(dashed red line), 12.3 nmol/l (solid red line), 37 nmol/l (dashed green
line), 111 nmol/l (solid green line), 333 nmol/l (dashed blue line) and
1 μmol/l (solid blue line). Vehicle group is shown in black. (b) Dose–
response curves of GLP-1 in the presence of exendin 9–39 at varying
concentrations in CHO cells overexpressing mouse GLP1R.
Concentrations of exendin 9–39 were: 1.9 nmol/l (solid red line),
5.6 nmol/l (dashed red line), 16.8 nmol/l (solid green line), 50 nmol/l
(dashed green line), 151 nmol/l (solid blue line), 453 nmol/l (dashed blue
line) and 1.36μmol/l (solid orange line). Vehicle group is shown in black.
(a, b) Data are mean ± SE from duplicate wells; data are representative of
at least three independent experiments. (c) Schild plot analysis of dose–
response curves for Glp1R0017 (triangles) and exendin 9–39 (circles).
Dose ratio (DR) is the ratio of the apparent GLP-1 EC50 in the presence of
Glp1R0017 at a set concentration, over the GLP-1 EC50 in the absence of
Glp1R0017. Points from three independent experiments are plotted, to-
gether with the 95%CI band for each line. The Schild plot x-axis intersect
yields dissociation constant values of 466 pmol/l for Glp1R0017, and
315 pmol/l for exendin 9–39
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The ability of Glp1R0017 to block GLP1R in vivo was
assessed by both IPGTT and OGTT in C57/Bl6 mice. An
IPGTTwas used to determine the antibody’s ability to inhibit
the effect of the GLP-1 analogue liraglutide. Pre-treatment for
24 h with Glp1R0017 dose-dependently reversed the effect of
liraglutide on glucose tolerance in IPGTTs (Fig. 6a, b).
Glp1R0017 at 19.2 mg/kg completely abolished the effect of
liraglutide on glucose tolerance, such that there was no signif-
icant difference in AUC compared with the vehicle-only
group (Fig. 6b). This indicated that Glp1R0017 inhibits the
GLP1R function in vivo.
To determine the ability of Glp1R0017 to block the endog-
enous incretin action of GLP-1, an OGTT was used.
Glp1R0017 was dosed alone (9.6 mg/kg) or in combination
with the GIPR antagonistic antibody Gipg013 (100 mg/kg) to
block both the GIP and GLP-1 components of the incretin
effect [16]. Gipg013 dosed alone did not have an effect on
glucose tolerance. However, when Glp1R0017 was dosed
alone, there was a small reduction in glucose tolerance com-
pared with the isotype antibody control group (p < 0.05; Fig.
6c, d). When both GIPR- and GLP1R-mediated components
of the incretin effect were blocked, glucose tolerance was
further reduced (p < 0.001) compared with the isotype control
antibody group (Fig. 6c, d). Hence, both antibodies are able to
inhibit the action of endogenous incretin hormones on
glucose-stimulated insulin secretion.
Discussion
Amonoclonal antagonistic antibody, Glp1R0017 targeting the
GLP1R with nanomolar affinity has been generated using
naive phage display. Schild regression analysis showed that
Glp1R0017 antagonism of GLP1R is surmountable, as the
maximal receptor activity was achieved with increasing com-
peting concentrations of GLP-1. This suggests that
Glp1R0017 is a competitive antagonist, although the slope
of the Schild plots for Glp1R0017 and exendin 9-39 did not
equal 1. This may suggest that equilibrium between antagonist
and agonist had not been reached at the time of cell lysis
within the cAMP assay, or that the inhibition was not a simple
competition for the same binding site and the calculated dis-
sociation constant should only be taken as an estimate.
Glp1R0017 not only inhibited cAMP production from the
GLP1R, but also reduced the GLP-1-triggered increase in
glucose-stimulated insulin secretion. Of interest, when
assessing the effect of Glp1R0017 on insulin secretion from
INS-1 832/3 cells, Glp1R0017 also significantly reduced
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Fig. 3 Glp1R0017 reduces GLP-1-stimulated cAMP and insulin secre-
tion in the INS-1 832/3 cell line. (a) Example graph of changes in cAMP
concentration in response to GLP-1 receptor activation. INS-1 832/3 cells
transfected with Epac2-camps, to enable measurement of cAMP by
FRET, were perfused with GLP-1 (100 nmol/l) followed by forskolin/
IBMX (F/I; 10 μmol/l or 100 μmol/l), as indicated. (b) Example graph of
changes in cAMP concentration following a 15 min preincubation with
1 μmol/l Glp1R0017. (c) Mean changes in the CFP/YFP emission ratio.
Data are mean ± SEM; n = 19 for antibody-treated cells, and n = 26 for
cells without antibody (monitored in 9–11 independent experiments per
condition). Statistical significance was assessed by one-way ANOVA
with post hoc Bonferroni test. ***p < 0.001. (d) Insulin secretion from
INS-1 832/3 cells expressed relative to basal secretion in 8.3 mmol/l
glucose measured in parallel on the same day. Cells were incubated with
(black bars) and without (white bars) 100 nmol/l Glp1R0017. Data are
mean ± SEM, n = 9–18 wells (from triplicates in 3–6 independent exper-
iments). Statistical significance was assessed by one-way ANOVAwith
post hoc Bonferroni test. *p < 0.05, **p < 0.01, ***p < 0.001
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insulin secretion in 8.3 mmol/l glucose without added GLP-1
(1–0.70-fold, p < 0.05). On further investigation, we found
that GLP-1 was produced by INS-1 832/3 cells, increasing
from 16.0 ± 1.6 pg/ml at 2 mmol/l glucose to 55.3 ± 3.0 pg/
ml at 8.3 mmol/l glucose (p < 0.001, n = 9 wells) in the
supernatant fraction, which probably explains the observed
antibody effect in the absence of added GLP-1. Although
GLP-1 secretion in the vicinity of INS-1 832/3 cells is hard
to estimate, the observed inhibition suggests that the antibody
can compete with very low effective GLP-1 concentrations in
the picomolar range. In light of the endogenous GLP-1 secre-
tion by INS-1 832/3 cells, this cell line could not be used to
analyse antibody off-target effects on insulin secretion trig-
gered by submaximal concentrations of GIP or other Gs-
coupled stimuli.
Immunostaining of the mouse pancreas with Glp1R0017
can be compared with that recently reported with 7F38A2
[24]. Both antibodies immunostained the beta cells of the is-
lets of Langerhans in a GLP1R-dependent fashion. The
Glp1R0017 cross-species reactivity, shown by the cAMP
HTRF assay, suggests that immunostaining tissue from differ-
ent species should be possible with Glp1R0017. This would
complement immunostaining with MAb 3F52, which shows
GLP1R localisation in monkey and human tissue [5]. MAb
3F52 has been characterised as an antagonistic antibody that
directly blocks the GLP-1-binding site of human GLP1R [25];
characterisation of 7F38A2 antagonistic activity has, howev-
er, not yet been published. Glp1R0017 adds to these antibod-
ies, providing an additional tool for studying GLP1R physiol-
ogy in rodents and the other species (cynomolgus monkey,
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bFig. 4 Glp1R0017
immunostains GLP1R within the
Islets of Langerhans in mouse
pancreas tissue. (a) Fixed
pancreas sections from Glp1r-
Cre/ROSA26-tdRFP mice were
co-immunostained for RFP,
insulin and GLP1R (using
Glp1R0017). Nuclei were
visualised with Hoechst stain.
Scale bars, 20 μm. (b) Fixed
pancreas sections from Glp1r−/−
mice were co-immunostained for
glucagon, insulin and GLP1R
(using Glp1R0017). Scale bars,
20 μm. (c) Sections of 25 μm
from the hypothalamus of Glp1r-
Cre/ROSA26-tdRFP mice were
co-immunostained for RFP and
GLP1R using Glp1R0017. Nuclei
were visualised with Hoechst
stain. Scale bars, 100 μm
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Fig. 5 Glp1R0017 reaches Cmax in 24 h when dosed subcutaneously,
compared with 4 h when dosed intraperitoneally. Glp1R0017 was dosed
at 19.2 mg/kg to two groups (n = 6) intraperitoneally (circles) and sub-
cutaneously (squares), respectively. The concentration of antibody in
plasma was then measured over 5 days (n = 3 at each time point).
Three samples were taken per time point from 0.5 h to 96 h, with one
sample missing at 0.5 h in the subcutaneous group and one at 72 h in the
intraperitoneal group
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dog and human) with which it was cross-reactive. The speci-
ficity of Glp1R0017, demonstrated across a range of assays,
provides a major benefit when compared with the peptide
antagonist exendin 9-39, which has been shown to have off-
target effects [12], although we cannot exclude potential inter-
actions with unknown targets.
The in vivo ability of Glp1R0017 to inhibit GLP1R is a key
finding of this study. Based on the pharmacokinetic study, it is
estimated that the biological half-life of Glp1R0017 is longer
than 120 h. Thus, with repeated doses, Glp1R0017 could be
used to investigate chronic inhibition of GLP1R. The avail-
ability of both a GLP1R antagonistic antibody Glp1R0017,
and a GIPR antagonistic antibody Gipg013 [16], enables in-
vestigation of the enteroinsular axis in vivo. The OGTT results
are in line with GTT data from Glp1r−/− and Gipr−/− mice as,
in both cases, only mild effects on glucose tolerance were
observed in the individual knockout mice and single-
antibody-treated animals [23, 26], whereas the combination
of GLP1R and GIPR antibodies had a marked effect on glu-
cose levels following the GTTs. These results support the idea
that the two incretin hormones can compensate for each other,
at least in part. A similar conclusion was reached in studies
using single or double incretin receptor knockout mice [27].
Our finding that a single dose of Gipg013 did not significantly
affect oral glucose tolerance, whereas Glp1R0017 caused a
small but significant increase in plasma glucose levels after
the OGTT, suggests that GLP-1 may be more important than
GIP for the incretin effect in this mouse model, contrasting
with studies using single and double incretin receptor knock-
out mice, which concluded that GIP was the more important
incretin hormone [27].
The IPGTTs demonstrated that Glp1R0017 was able to
block the effect of exogenously dosed liraglutide. This prop-
erty of Glp1R0017 could be applied to the study of GLP-1
containing dual or triple agonists, which are emerging for the
treatment of type 2 diabetes [28, 29]. These agonists are based
on the concept that gastric bypass surgery, which commonly
resolves the symptoms of type 2 diabetes, does not solely
target one molecular pathway [30]. The balance of the differ-
ent components within multi-agonists is important in devel-
opment [14]; thus, Glp1R0017may be useful for investigating
the importance of the GLP-1 component within these
agonists.
The ability of Glp1R0017 to block GLP1R in vivo opens
up the possibility of studying extrapancreatic effects of GLP-1
in multiple species due to its cross-reactivity. There are a num-
ber of questions over how GLP-1 analogues exert the benefi-
cial cardiovascular effects observed in clinical trials [8–10]. In
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Fig. 6 Glp1R0017 inhibits GLP1R in C57/Bl6 mice. (a) At 24 h after
antibody dosing, and 2 h after liraglutide treatment (0.1 mg/kg), IPGTTs
(2 g/kg) were performed. Vehicle only (circles), liraglutide only (squares)
and liraglutide plus 19.2 mg/kg (upright triangles), 6.4 mg/kg (inverted
triangles) and 3.1 mg/kg (diamonds) Glp1R0017. (b) AUC for glucose
between 0 and 120min. Data are mean ± SEM (n = 8). Comparisons were
made with the liraglutide-only group, and statistical significance was
assessed by one-way ANOVAwith post hoc Bonferroni test. *p < 0.05,
***p < 0.001. (c) At 24 h after antibody dosing, OGTTs (2 g/kg) were
performed. Circles, R347 isotype control 10 mg/kg; squares, Glp1R0017
9.6 mg/kg; upright triangles, Gipg013 100 mg/kg; inverted triangles,
Glp1R0017 9.6 mg/kg with Gipg013 100 mg/kg. (d) AUC for glucose
between 0 and 120min. Data are mean ± SEM (n = 8). Comparisons were
made with R347 group, and statistical significance was assessed by one-
way ANOVAwith post hoc Bonferroni test. *p < 0.05, ***p < 0.001
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summary, the GLP1R antagonistic antibody Glp1R0017, de-
veloped and extensively characterised here, provides a novel
tool for investigating the GLP-1 component of unimolecular
dual agonists for the treatment of type 2 diabetes, and for
further understanding the physiology of GLP1R in vitro and
in vivo. Glp1R0017 provides a new method to block GLP-1
receptors over several days in a range of species. It comple-
ments the use of Glp1r knockout mice by enabling transient
and/or age-restricted GLP1R blockade, and may have advan-
tages over exendin 9–39 when it is important to exclude po-
tential cross-reactivity with related GPCRs.
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